Dr Luiza Steffens Reinhardt is an early career researcher who has developed a skillset in molecular biology and human genetic as means to tackle cancer therapy resistance. Dr Steffens Reinhardt recently completed her PhDs (PhD of Biosciences, UFCSPA 2022 and PhD of Medical Genetics, UoN 2023). Since then, she has been working in translational cancer research within the HMRI’s Cancer Detection and Therapy Research Program.

Dr Steffens Reinhardt is an author on 39 publications (twelve as first author), including publications in reputable journals such as Cell Death and Disease and BBA Reviews in Cancer and six book chapters (all as first author). Luiza has been cited 646 times, have an H-index of 16, has already obtained over $1.4 million in competitive grants, funding, and awards.

Dr. Steffens Reinhardt has extensive expertise in a wide range of pre-clinical models, which have led to significant discoveries, including novel markers for breast cancer recurrence (IJMS. 2022 23(12):6670; IJMS 2023(24):10078) and treatment resistance (Cell Death Dis. 2022(13):907; Cell Death Dis. 2023(14):509). Her research has garnered substantial media attention, highlighting its clinical relevance.

Currently, Dr. Steffens Reinhardt’s work focuses on validating and implementing advanced genomic tests. Her primary project centres on leveraging long-read sequencing to address complex genetic variants associated with hereditary cancer predisposition syndromes. Additionally, working with Professor Hubert Hondermarck and Dr Jiang, her research is investigating novel therapeutic targets for HER2+ breast cancers resistant to standard therapies.

Dr. Steffens Reinhardt’s research is driven by a commitment to bridging the gap between scientific discovery and clinical application, aiming to address critical challenges in cancer therapy and improve patient outcomes.